Biosimilares/Investigación

Positive phase I results for Meiji’s ustekinumab biosimilar

Biosimilares/Investigación | Posted 04/06/2021

Japan-based Meiji Seika Pharma (Meiji) announced on 21 May 2021 positive phase I results for its candidate ustekinumab biosimilar, DMB-3115.